{"id":"carboquone","rwe":[],"tags":[{"label":"carboquone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01AC03","category":"atc"},{"label":"Active","category":"status"},{"label":"Alkylating Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Alkylating","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"esquinone","offLabel":[],"synonyms":["carboquone","carbazilquinone","esquinone"],"timeline":[],"brandName":"Esquinone","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"carboquone","explanation":"Think of it like a roadblock for cells to make copies of their DNA. This can help slow down or stop the growth of cancer cells, but it can also affect healthy cells. As a result, the body may experience side effects like fatigue, nausea, and hair loss.","oneSentence":"Esquinone works by inhibiting DNA synthesis, which is essential for cell growth and division.","technicalDetail":"Carboquone is a quinone-based compound that acts as a DNA synthesis inhibitor, likely through the disruption of the electron transport chain and subsequent inhibition of the enzyme ribonucleotide reductase."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/503","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CARBOQUONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:11:58.420136","biosimilars":[],"competitors":[{"drugName":"thiotepa","drugSlug":"thiotepa","fdaApproval":"1959-03-09","patentExpiry":"May 31, 2037","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"carboquone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"thiotepa","brandName":"thiotepa","genericName":"thiotepa","approvalYear":"1959","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"1CB0HBT12C","CHEBI":"CHEBI:31356","INN_ID":"3651","UMLSCUI":"C0006971","ChEMBL_ID":"CHEMBL443014","KEGG_DRUG":"D01270","DRUGBANK_ID":"DB13677","PUBCHEM_CID":"2569","MESH_DESCRIPTOR_UI":"D002225"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":170,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01AC03","allCodes":["L01AC03"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Esquinone, also known as carboquone, is a small molecule drug in the carboquone class. Its target and exact mechanism of action are unknown, but it is believed to work by inhibiting DNA synthesis. Esquinone is not FDA-approved for any indications, and its commercial status, including patent and generic availability, is unclear. Key safety considerations are not well-documented due to its lack of FDA approval. Further research is needed to fully understand its effects and potential uses.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}